Overview

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

Status:
Recruiting

Trial end date:
2031-04-30

Target enrollment:

Participant gender:

Summary

The intention of the study is to demonstrate superiority of Saruparib (AZD5305) + physician's choice NHA relative to placebo + physician's choice NHA by assessment of radiographic progression-free survival (rPFS) in participants with mCSPC.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Abiraterone Acetate